More than three years after the first chimeric antigen receptor (CAR) T-cell therapy achieved U.S. Food and Drug Administration (FDA) approval, the revolutionary approach that has upended blood cancer treatment continues to generate excitement.
With the COVID-19 pandemic driving yet another science conference to the virtual world, it is fitting that the 62nd ASH Annual Meeting and Exposition officially kicked off today with a virtual fireside chat via live stream featuring none other than Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, and a member of the administration’s coronavirus task force.
Here at The Leukemia & Lymphoma Society (LLS), we hear from blood cancer patients and caregivers each day about the profound effects of the COVID-19 pandemic on their cancer care, treatment, and daily lives.
In 2007, when I served as The Leukemia & Lymphoma Society’s Chief Scientific Officer, I conceived and launched the LLS venture philanthropy initiative, the Therapy Acceleration Program (TAP). Our goal was to expand beyond traditional research grants and to bring much-needed therapies into clinical studies faster. And I’m pleased to share we’ve made a real impact.
LLS & BURLINGTON STORES SURPRISE PEDIATRIC CANCER SURVIVORS WITH ONE-OF-A-KIND OUTDOOR “PATIENT PARADES” AT SELECT STORE LOCATIONS NATIONWIDE
As part of Burlington’s annual in-store fundraising campaign, they’re hosting celebratory drive-by ‘parades’ for children battling cancer...